Details for New Drug Application (NDA): 214402
✉ Email this page to a colleague
NDA 214402 describes CEFEPIME HYDROCHLORIDE, which is a drug marketed by Acs Dobfar, Astral, Chartwell Rx, Hikma, Hospira Inc, Qilu Antibiotics, Sagent Pharms Inc, and Samson Medcl, and is included in nine NDAs. It is available from eight suppliers. Additional details are available on the CEFEPIME HYDROCHLORIDE profile page.
The generic ingredient in CEFEPIME HYDROCHLORIDE is cefepime hydrochloride. There are twenty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the cefepime hydrochloride profile page.
The generic ingredient in CEFEPIME HYDROCHLORIDE is cefepime hydrochloride. There are twenty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the cefepime hydrochloride profile page.
Summary for 214402
| Tradename: | CEFEPIME HYDROCHLORIDE |
| Applicant: | Hikma |
| Ingredient: | cefepime hydrochloride |
| Patents: | 0 |
Suppliers and Packaging for NDA: 214402
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CEFEPIME HYDROCHLORIDE | cefepime hydrochloride | INJECTABLE;INJECTION | 214402 | ANDA | Hikma Pharmaceuticals USA Inc. | 0143-9382 | 0143-9382-10 | 10 VIAL in 1 CARTON (0143-9382-10) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL |
| CEFEPIME HYDROCHLORIDE | cefepime hydrochloride | INJECTABLE;INJECTION | 214402 | ANDA | Hikma Pharmaceuticals USA Inc. | 0143-9383 | 0143-9383-10 | 10 VIAL in 1 CARTON (0143-9383-10) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | May 22, 2024 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL | ||||
| Approval Date: | May 22, 2024 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
